Profesionales médicos

A continuación, se enumeran los ensayos clínicos actuales.

269 estudios en Cancer
(solo estudios abiertos).

Filtra esta lista de estudios por sede, estado, etc.

1. A Study To Evaluate The Surgical Removal Of Residual Brain Tumors Prior To Recurrence

   Rochester, Minn.

   The purpose of this study is to evaluate the safety and feasibility of surgical resection for pre-recurrent brain tumors. Eligible patients with surgically accessible latent tumors desiring surgical resection will be enrolled to prospectively track short- and long-term outcomes. Safety will be evaluated by quantifying rates of surgical morbidity as compared to patients undergoing RT after surgery, or no surgery for similar latent disease. Variables evaluated will include postoperative complications including death within 30 days, wound infection, length of hospital stay, and readmission rates.

    

    

2. Ommaya Placement For Biomarker Collection

   Rochester, Minn.

   The purpose of this study is to determine the safety and feasibility of intra-operative Ommaya Reservoir placement during a clinically indicated tumor surgery in order to facilitate a longitudinal access to cerebrospinal fluid (CSF) for analysis of exploratory and future tumor biomarkers for individualized monitoring.

    

    

3. A Study to Evaluate Performance of Coagulation Laboratory Testing in Children and Young Adults

   Rochester, Minn.

   The primary purpose of this study is to generate pediatric-specific reference ranges that take into account patient sex, age, corrected gestational age, ethnicity, etc., and laboratory variables for various coagulation studies.

4. A Study to Collect Data and Blood Samples from Mayo Patients Who Have or are Suspected of Having Amyloidosis, or Their Family Members, for Future Research

   Rochester, Minn.

   The purpose of this study is to create a data collection and bioregistry of blood samples from Mayo Clinic patients with amyloidosis, suspected amyloidosis, and family members of patients with amyloidosis. This information will be available for future research about this spectrum of diseases.

5. A Dose-Escalation And Expansion Study Of BGB-16673 In Participants With B-Cell Malignancies

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

6. Infection Outcomes Assessment of Absorbable Antibacterial Soft Tissue Support in Breast Reconstruction

   Rochester, Minn.

   The purpose of this study is to demonstrate the safety and effectiveness of the Melodi Absorbable Antibacterial Matrix for soft tissue support in immediate, two-stage postmastectomy alloplastic prepectoral breast reconstruction, to support an FDA Premarket Approval (PMA) Application.

7. Understanding The Relationship Between Benign Breast Tissue, Benign Breast Disease, And Breast Cancer Development

   Jacksonville, Fla.

   The purpose of this study is to culture human mammary cells to identify cellular characteristics associated with lobular involution status. 

8. SULF1 and SULF2 Role in Cholangiocarcinoma

   Rochester, Minn.

   Cholangiocarcinoma (CCA) has key similarities with HCC, therefore, we hypothesize that Sulf1 and Sulf2 may also play roles in promotion of CCA progression.

9. Monoclonal Proteins by Blood Spot and Saliva

   Rochester, Minn.

   The purpose of this study is to assess the feasibility and develop procedures for detecting monoclonal proteins via finger pick blood spots and saliva. Data will be compared to results of serum data collected for patient care during the same time.  The test will be evaluated qualitatively against venipunctured data tested by Mass Fix.

10. A Study Of ABBV-383 With Relapsed Refractory Waldenström Macroglobulinemia

    Rochester, Minn.

    The purpose of this study is to determine the safety, maximum tolerated dose (MTD) and RP2D of ABBV-383 monotherapy for patients with RRWM and to determine VGPR or deeper response as the best response achieved with ABBV 383 within 12 cycles  of initiation of therapy for patients with RRWM.